hotspot -WSS

hotspot

author：knowledge 2025-09-27 23:32:19 - browse：187

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： House panel takes first step toward fixing drug shortages

WSS

A Theranos scientist

A Theranos scientist

Robert Kennedy Jr.'s presidential campaign attracts GOP

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Manchin plays down potential 3rd

David Liu startup to focus on CRISPR delivery

leisure time

hotspot

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Akili changes sales model for its ADHD video game treatment

Psychedelics group wrestles with new pharma identity

Robert Kennedy Jr.'s presidential campaign attracts GOP

Dobbs anniversary: the lost opportunity of abortion as health care

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Information blocking fines are now fair game in health care

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA seeking to stop procedures at two unregulated stem cell clinics

explore

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Chamber of Commerce, DOJ clash in court over drug prices

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Why the quest to eradicate polio has stumbled

Lack of darker skin in textbooks, journals harms patients of color

Patients, doctors press FTC to beef up hospital merger scrutiny

leisure time

hotspot

Wikipedia

knowledge